PRLog - July 26, 2011 - NAPERVILLE, Ill. -- Biomarkers feature in thousands of published articles each year, evidencing the high level of interest and research in this field. This report focuses on issues that must be addressed to utilize this growing knowledge about biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication:
Reportstack Market Reports
Biomarker definitions and guidelines for their development and validation
Applications of biomarkers in oncology, cardiology, neurology, drug safety, and other areas
Selected companies in the biomarker research products/tools and services market
Strategies for successful commercialization of biomarkers in the therapeutics and diagnostics markets
Forty key companies to watch, plus the activities of 175 companies that are commercializing biomarkers and/or systems for their detection and measurement
Biomarkers can be valuable tools in clinical diagnostics as well as in therapeutic discovery and development. They can be used to predict response to therapy or risk of side effects for personalized medicine applications. Additional types include predisposition, screening, diagnostic, prognostic, toxicity, pharmacodynamic, and other biomarkers.
Commercializing Biomarkers in Therapeutic and Diagnostic Applications:
Next, examples are provided of the wide range of current and potential emerging applications of biomarkers in different fields such as oncology, cardiology, neurology, safety, and others. An examination of the market for research products (tools) and services in the field of biomarkers includes a discussion of selected companies and their activities, plus agreements and acquisitions in this area.
As part of a dual focus, Commercializing Biomarkers in Therapeutic and Diagnostic Applications:
Similarly, this report also focuses on biomarker strategies for therapeutic development. This includes a discussion of the potential roles of biomarkers in various aspects of drug development, validation of biomarkers, regulatory issues, options for companies developing drug/diagnostic combinations, health economics and reimbursement in personalized medicine, and other issues. Also included is a compilation of agreements between pharmaceutical and diagnostic companies.
Forty key companies to watch are identified, plus 175 companies that are commercializing biomarkers and/or systems for their detection and measurement. The report concludes with Insight Pharma Reports’ interviews with experts in this field.
Browse other Pharma & Healthcare Industry related reports at:
# # #
Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world’s top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit http://www.reportstack.com